ILA
Pharmaceuticals, Biotechnology & Life Sciences
Island Pharmaceuticals
- Short interest
- <0.01%
- 0.00 pp 30d
- as of 9 Nov 2026
- Reported shorts
- 4
- Shares on issue
- 296.097M
Latest articles and price-sensitive announcements with AI sentiment classification.
The United States Army Medical Research Institute of Infectious Diseases has started scheduled surgical procedures for 22 non-human primates, allocated ... Read More The post Island Pharmaceuticals advances Marburg study towards December dosing appeared first on Stockhead.
other announcement
Bike riders and island residents joined forces with a haze of adrenaline, nostalgia and bittersweet sense of loss to farewell Phillip Island's MotoGP.
other announcement
other announcement
What Is Driving Island Pharmaceuticals (ASX:ILA) Shares Lower Today? Kalkine
other announcement
The Victorian government has announced a five-year deal to bring the Supercars to Phillip Island, helping offset an $80 million loss caused by losing the MotoGP.
Island Pharmaceuticals Limited (ASX:ILA) announced the issuance of 500,000 unquoted options to company consultants, each with an exercise price of $0.55 and an expiry date of 26 August 2029, as detailed in an Appendix 3G filing dated 9 October 2026. Key Points 500,000 options granted to ILA consultants on 26 August 2026 under an employee incentive scheme Options exercisable at $0.55 each, expiring on 26 August 2029 Vesting schedule: 50% on 26 August 2027 and remaining 50% on 26 August 2028 Bo...
other announcement
Island’s shot at gaining US FDA approval for antiviral Galidesivir for Marburg virus under the Animal Rule presents lucrative opportunities. ... Read More The post Island Pharma’s FDA Animal Rule route to big vouchers, bigger contracts appeared first on Stockhead.
The company says PI Health Sciences started GMP production of the drug’s active pharmaceutical ingredient on October 1, with the ... Read More The post Island Pharmaceuticals starts Galidesivir production for Ebola emergency-use program appeared first on Stockhead.
other announcement
We're Interested To See How Island Pharmaceuticals (ASX:ILA) Uses Its Cash Hoard To Grow simplywall.st
other announcement
RAAS noted that an additional stockpile of Galidesivir rapidly strengthened Island Pharmaceuticals’ ability to respond to an ongoing Bundibugyo Ebola ... Read More The post Island Pharmaceuticals has almost 250% upside to research group’s valuation appeared first on Stockhead.
other announcement
Island Pharmaceuticals (ASX:ILA) Extends 122% One-Year Gain as Infectious Disease Pipeline Broadens Kalkine
other announcement
Highlights Island Pharmaceuticals has sought quotation of additional shares, putting capital structure and equity administration back in view. The company remains an early-stage healthcare developer, making clinical execution, regulatory progress and funding discipline central to the story. The next meaningful evidence will come from how new equity supports antiviral development milestones rather than from the quotation process alone. Island Pharmaceuticals (ASX:ILA) is back in view after see...
A Scottish swimmer rejects an approach to appear on a dating reality show and Idi Amin's grandson reveals his royal plans. Here are the quick hits from day six of the Commonwealth Games.
Island Pharmaceuticals is confident that its acquired drug Galidesivir can make a difference to the Ebola outbreak sweeping central Africa. ... Read More The post Biocurious: Post Germageddon, Island Pharma will keep the US ticking over appeared first on Stockhead.
Highlights Island Pharmaceuticals has moved to deploy its antiviral candidate to help treat patients caught in an Ebola outbreak in Uganda. The humanitarian deployment offers a rare real-world setting to observe the compound outside a formal trial. The news lands amid a broad rebound in Australian healthcare shares from recent lows. Island Pharmaceuticals (ASX:ILA), the Sydney-based clinical-stage developer focused on repurposing antiviral compounds against dangerous ...
Managing director unpacks series of major milestones achieved across Galidesivir, Marburg and dengue clinical programs. ... Read More The post Long Shortz with Island Pharmaceuticals: Ebola, Marburg and Dengue clinical programs advance appeared first on Stockhead.
If Galidesivir demonstrates efficacy, the program’s result may support future government procurement, biodefence stockpiling and broader commercialisation opportunities. ... Read More The post Island Pharma gets green light to use Galidesivir in Ebola outbreak appeared first on Stockhead.
Why Island Pharmaceuticals (ASX:ILA) Shares Are Trading Higher On Tuesday? Kalkine
other announcement
Island Pharmaceuticals (ASX:ILA) Falls as Investors Reassess Clinical-Stage Biotech Risks Kalkine
Island Pharmaceuticals (ASX:ILA) Advances IP Strategy with Singapore Patent Kalkine
other announcement
The Phillip Island community is coming to terms with the loss of another major sporting event with South Australia claiming the rights to Australia's Superbike World Championship race from 2028.
other announcement
Island Pharmaceuticals has expanded its US army collaboration, to further its groundbreaking candidate Galidesivir for treating Marburg Virus Disease. ... Read More The post Island expands its US biodefence collaboration for heavy-hitting virus study appeared first on Stockhead.
other announcement
other announcement
Highlights Leadership transition underway at Middle Island Resources Executive Chairman takes charge during transition phase Serbian mineral assets remain central to company strategy Middle Island Resources enters a new leadership phase as the company restructures executive responsibilities while maintaining focus on exploration activities and long-term development plans across its mineral assets. Middle Island Resources (ASX:MDI) has entered a new chapter following a significant execut...
other announcement
Highlights Island Pharmaceuticals advances antiviral research Debt-free position supports long-term focus Analysts anticipate a shift toward profitability Island Pharmaceuticals is drawing investor attention as its antiviral development pipeline progresses alongside a debt-free balance sheet and growing expectations around future profitability. Island Pharmaceuticals Limited (ASX:ILA) is increasingly gaining attention across the Australian biotechnology sector as investors closely watch...
Island Pharmaceuticals (ASX:ILA): Ebola outbreak puts antiviral stocks in focusIsland Pharmaceuticals (ASX:ILA): Ebola outbreak puts antiviral stocks in focus Kalkine
Island Pharmaceuticals appoints a senior security advisor and advances preparation for its Galidesivir clinical trial. ... Read More The post Break it Down: Island expands US biodefence engagement ahead of Galidesivir studies appeared first on Stockhead.
ASX
Stockhead
Google News
Kalkine
Small Caps